Citations

Clear

53 citation(s) found for "Anastasiadis, P Z".

Longitudinal Surgical Modeling of Early Glioblastoma Recurrence Reveals Emergence of Margin-Associated Neural Programs
Malla, Adarsha P. , Flick, Matthew , Fang, Jennifer R. , Fan, Xiaoxuan , Chen, Chixiang , Beniwal, Angad , Sereduk, Chris , Drexler, Richard , Poulopoulos, Alexandros , Monje, Michelle , Anastasiadis, Pavlos , Tran, Nhan L. , Winkles, Jeffrey A.

Mayo Clinic

Cancer Research | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF20

10.1158/0008-5472.can-25-5176 | PMID 42831833 Get It

Abstract Glioblastoma (GBM) is a lethal, treatment-resistant brain cancer characterized by diffuse brain invasion, complex neuron–glioma signaling, and cellular, molecular, and spatial heterogeneity. Surgery is the current mainstay of treatment, aimed at maximizing tumor cytoreduction, decompressing the brain to improve neurologic function and providing material for analyses to inform prognostication and adjuvant treatment selection. To accurately model GBM surgical resection and tissue sampling in preclinical animal models, we developed the Maximal Safe Intracranial Surgery (MSIS) platform. MSIS integrated a miniaturized neurosurgical resection device and enabled a safe, tunable, and reproducible approach for intracranial tumor resection, multiregional biopsy, and longitudinal tissue sampling in murine models, with stereotactic, sterile, and high-viability tissue collection. MSIS was applied across five distinct orthotopic brain tumor models to reproducibly generate histologically and radiologically representative models of postsurgical GBM. Similar to humans, increasing the extent of resection correlated with improved animal survival, and recurrent growth patterns varied significantly by model type. Transcriptional profiles of matched primary versus postsurgical recurrent tumors revealed enrichment of margin-associated transcriptional states consistent with neuron–glioma signaling. Overall, the MSIS approach offers opportunities to model the standard of care, dissect the spatial and temporal dynamics of GBM, and pair therapeutic discovery with contextual tumor pathobiology. Significance: A clinically derived stereotactic resection platform models surgical resection in glioblastoma, enabling longitudinal tissue sampling and revealing conserved early-recurrence neuron-glioma programs in patient-derived models.
Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Garcia, David M., Lin, Wan‐Hsin , Wickland, Daniel P. , Jessen, Erik , Middlebrooks, Erik H. , Haydu, Lauren E. , Brooks, Mieu , Feathers, Ryan W. , Kinsella, Lindsey , Sereduk, Chris , Rosenfeld, Steven S. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Jessen, Erik , Tran, Nhan L , Chaichana, Kaisorn L , Anastasiadis, P Z , Quinones-Hinojosa, Alfredo , Middlebrooks, Erik H , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag139 | PMID 42296327 Get It

Abstract Background Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
Plekha7 promotes retina organization and inhibits inflammation and photoreceptor loss
Cooper, Lisa M. , Chen, Jiaxiang, Lu, Ruifeng, Feathers, R., Lin, Wan-Hsin, Anastasiadis, Panos Z. , Chen, Jiaxiang , Lin, Wan‐Hsin

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.716333 Get It

Abstract Plekha7 associates with p120 catenin and localizes at apical cell-cell junctions where it has been implicated in junction stabilization. However, it’s in vivo function and underlying mechanisms of action remain unclear. Here, we show that constitutive Plekha7 loss in mice disrupts retinal organization, reduces retinal thickness, and induces RPE multinucleation, microglia infiltration, and photoreceptor loss. Plekha7 deficiency reduces the accumulation of cadherin–catenin complexes at apical junctions without altering overall cadherin levels, indicating a defect in junctional maintenance. Mechanistically, PLEKHA7 regulates cadherin trafficking by limiting levels of endocytosed E-cadherin, thereby maintaining junctional cadherin pools. Notably, these effects are largely independent of p120 catenin. In addition, further Plekha7 roles in the regulation of centrosome, cilia, microtubule dynamics, and cytokinesis, likely contribute to the phenotypic changes induced by Plekha7 knockout. These findings establish Plekha7 as a key regulator of cadherin trafficking and epithelial organization with relevance to retinal disease.
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, Wan-Hsin, Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan, Hall, Jamie, Sadeghian, Dorsay , Johnson, Sarah H. , Harris, Faye R. , Berry, Taylor, McCune, Alexa, Murphy, Stephen James, Kinsella, Lindsey, Ensign, Shannon P. Fortin, Yang, Lin , Emanuel, Angela, Jones, Leila A., Schaefer-Klein, Janet, Ida, Cristiane M., Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven, Kizilbash, Sani H., Jaeckle, Kurt A. , Mrugala, Maciej M., Borad, Mitesh, Bendok, Bernard R., Quiñones-Hinojosa, A., Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Ensign, Shannon P. Fortin , Mansfield, Aaron S , Ensign, Shannon P. Fortin , Sotiriou, Sotiris , Haydu, Lauren E. , Moniz‐Garcia, Diogo , Ida, Cristiane M., Salomao, Marcela , Kizilbash, Sani H. , Mrugala, Maciej M., Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C. , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.01.701806 | PMID 41676502 Get It

Abstract High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract
The TNFR superfamily member Fn14 impacts immunity and survival in experimental gliomas and response to immune checkpoint inhibitor therapy in glioblastoma patients
Kanvinde, Pranjali , Seas, Alexandra A. , McFarland, Emylee, Fang, Jennifer R. , Flick, M, Connolly, Nina P, Beniwal, Angad , Sharifai, Nima , Chen, Chixiang, Anastasiadis, Pavlos , Winkles, Jeffrey A. , Woodworth, Graeme F, Chen, Chixiang , Kanvinde, Pranjali P , Sharifai, Nima , Chen, Chixiang , Bar, Eli E , Winkles, Jeffrey A , Woodworth, Graeme F , Malla, Adarsha P. , Connolly, Nina P. , Yepes, Manuel A , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology Advances | February 3, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag023 | PMID 41853810 Get It

Abstract Background Fibroblast growth factor-inducible 14 (Fn14) belongs to the TNFR superfamily. Fn14 overexpression can drive receptor-autonomous signaling, increase both cell invasion and tumor-associated macrophages/microglia (TAMMs) recruitment, and correlates with reduced survival in glioblastoma (GBM) patients and rat gliomas. While prior studies report Fn14 expression in non-tumor cells within the GBM tumor microenvironment (TME), their relative contributions to glioma pathobiology remain unclear. Methods Using tumor-host pairings of Fn14-positive and -knockout (-KO) cells and mice, we examined the role of Fn14 in glioma biology. Mouse glioma and human GBM datasets were analyzed at the cellular, protein, and transcriptomic levels to assess Fn14-associated changes in the glioma TME and survival outcomes. Results Fn14 was found to be highly expressed in tumor cells and TAMMs in human GBM and 2 well-characterized murine glioma models. Fn14 KO in both tumor and host cells increased overall survival. Notably, this survival benefit was greater in the glioma model characterized by a more immunologically activated TME. Immunophenotyping revealed that Fn14 loss reshapes the tumor-immune landscape, reducing the presence of immunosuppressive macrophages and exhausted T-cells, suggesting that Fn14 modulates both innate and adaptive immune responses. These findings were supported by analyses of human GBM datasets, where high Fn14 expression correlated with immunosuppressive shifts and poor patient responses to immune checkpoint inhibitor therapy. Conclusions This study provides the first description of the contributions of both tumor- and host-derived Fn14 expression to tumor immunity and survival and identifies Fn14 as an important mediator of innate and adaptive immune responses in gliomas.
Rethinking psychological treatment targets for pediatric rumination syndrome: Clinical implications from a case series analysis
Anastasiadis, William A. , Gloe, Lilianne M. , Johnson-Kwochka, Annalee V. , Diest, Ashley M. Kroon Van , Lagges, Ann, Wagoner, Scott T. , Williams, Amy E. , Sparks, Brandon , Gilbert, Elaine

Mayo Clinic

JPGN Reports | August 7, 2025 | Volume: 6 | Issue: 4 | Pages: 382-386

10.1002/jpr3.70074 | PMID 41245029 Get It

Abstract Rumination syndrome (RS) is a common pediatric disorder of gut–brain interaction. However, a dearth of research on efficacious treatment to help guide clinical decision‐making remains. Thus, relying on well‐established treatment recommendations for other conditions with similar mechanisms or symptom profiles may be helpful; for example, conceptualizing RS treatment targets to address it as a “tic disorder of the gut” could be beneficial. To demonstrate the clinical utility of this conceptualization, we presented two cases that provide broad implications for treating pediatric RS. In both cases, akin to pediatric tic and related disorders, cognitive distress and physical discomfort were alleviated temporarily by rumination episodes. Thus, we recommend a targeted diagnostic assessment, including a functional analysis incorporating a transdiagnostic evaluation of symptoms. Close comanagement with specialty physicians and psychologists is also highly recommended. The patients represent complex yet standard cases seen in pediatric psychology outpatient clinics, suggesting the clinical utility of implications for psychologists and allied health professionals.
Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders
Yang, Lin , Lin, Wan-Hsin, Feathers, Ryan W. , Ayers-Ringler, Jennifer , Tolosa, Ezequiel J. , Kizhake, Amritha G., Kizhake, Smitha , Kubica, Sydney P., Boghean, Lidia , Naldrett, Michael J. , Rana, Sandeep , Schaefer-Klein, Janet, Roden, Anja C. , Kosari, Farhad , Anastasiadis, Panos Z. , Feathers, Ryan, Tolosa, Ezequiel, Roden, Anja, Natarajan, Amarnath , Mallareddy, Jayapal Reddy , Lin, Wan‐Hsin , Alvarez, Sophie , Singh, Sarbjit , Zahid, Muhammad , Borad, Mitesh J. , Natarajan, Amarnath , Mansfield, Aaron S.

Mayo Clinic

RSC Advances | April 4, 2025 | Volume: 15 | Issue: 13 | Pages: 10419-10425

10.1039/d5ra01441g | PMID 40182503 Get It

Despite ongoing efforts to employ structure-based methods to discover targeted protein degraders (TPD), the prevailing strategy remains synthesizing a focused set of heterobifunctional compounds and screening them for target protein degradation.
Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas
Ali, Mohamed F. , Riviere-Cazaux, Cécile , Johnson, Sarah H. , Salvatori, Rebecca , Penheiter, Alan R. , Smadbeck, James , Murphy, Stephen J. , Harris, Faye R. , McCune, Lex F. , Carlstrom, Lucas P. , Barrett, Michael T. , Kosari, Farhad , Jones, Leila A. , Quiñones‐Hinojosa, Alfredo , Porter, Alyx B. , Mrugała, Maciej M. , Jaeckle, Kurt A. , Anastasiadis, Panos Z. , Kizilbash, Sani H. , Cheville, John C. , Vasmatzis, George , Smadbeck, James B , Ida, Cristiane M , Borad, Mitesh J , Bendok, Bernard R , Quinones-Hinojosa, Alfredo , Porter, Alyx , Mrugala, Maciej M , Jaeckle, Kurt A , Anastasiadis, P Z , Kizilbash, Sani H , Cheville, John C , Routman, David M , Burns, Terry C , Vasmatzis, George , Harris, Faye R. , Ida, Cristiane M. , Borad, Mitesh J. , Bendok, Bernard R. , Routman, David M. , Burns, Terry C.

Mayo Clinic

Clinical Cancer Research | February 28, 2025 | Volume: 31 | Issue: 9 | Pages: 1700-1710

10.1158/1078-0432.ccr-24-3233 | PMID 40019927 Get It

Abstract Purpose: Monitoring disease progression in patients with high-grade gliomas (HGG) is challenging due to treatment-related changes in imaging and the requirement for neurosurgical intervention to obtain diagnostic tissue. DNA junctions in HGG often amplify oncogenes, making these DNA fragments potentially more abundant in blood than monoallelic mutations. In this study, we piloted a cell-free DNA approach for disease detection in the plasma of patients with HGG by leveraging patient-specific DNA junctions associated with oncogene amplifications. Experimental Design: Whole-genome sequencing of grade 3 or 4 isocitrate dehydrogenase–mutant or wild-type astrocytomas was utilized to identify amplified junctions. Individualized qPCR assays were developed using patient-specific primers designed for the amplified junction. ctDNA levels containing these junctions were measured in patient plasma samples. Results: Unique amplified junctions were evaluated by individualized semi-qPCR assays in presurgical plasma of 18 patients, 15 with tumor-associated focal amplifications and three without tumor-associated focal amplifications. high copy-number junctions were robustly detected in the plasma of 14 of 15 (93.3%) patients with amplified junctions and none of the controls. Changes in junction abundance correlated with disease trajectory in serial plasma samples from five patients, including increased abundance of amplified junctions preceding radiographic disease progression. Conclusions: In patients with grade 3 or 4 astrocytomas who had tumor-associated amplifications, patient-specific amplified junctions were successfully detected in assayed plasma from most patients. Longitudinal analysis of plasma samples correlated with disease trajectory, including cytoreduction and progression.
BIOM-59. INDIVIDUALIZED TUMOR-SPECIFIC AMPLIFIED DNA JUNCTIONS FOR PLASMA-BASED MONITORING IN PATIENTS WITH HIGH-GRADE GLIOMAS
Ali, Mohamed A. Mohamed , Riviere-Cazaux, Cécile , Johnson, Sarah H. , Salvatori, Rebecca , Penheiter, Alan R. , Smadbeck, James B. , Murphy, Stephen J. , Harris, Faye R. , McCune, Alexa, Barrett, Michael T. , Kosari, Farhad , Jones, Leila, Basil, Aleeshba , Quiñones‐Hinojosa, Alfredo , Porter, Alyx B. , Mrugała, Maciej M. , Jaeckle, Kurt A. , Anastasiadis, Panos Z. , Kizilbash, Sani H. , Cheville, John C. , Vasmatzis, George , Kizilbash, Sani H , Murphy, Stephen, Ida, Cristiane M. , Borad, Mitesh J. , Bendok, Bernard R. , Routman, David M. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii33-viii33

10.1093/neuonc/noae165.0131 Get It

Abstract Accurate response assessment in patients with high-grade gliomas (HGGs) is complicated by post-treatment radiographic changes that are equivocal for treatment effect versus progression. Plasma-based liquid biopsy assays for circulating tumor DNA (ctDNA) have had limited sensitivity to date, due in part to the presence of the blood-brain barrier that limits the diffusion of tumor-derived analytes out of the central nervous system. To address this challenge, we developed a ctDNA plasma-based assay to detect individualized tumor-derived amplified junctions in patients with HGGs. These junctions occur due to large-scale chromosomal rearrangements, such as those associated with epidermal growth factor receptor (EGFR) or cyclin-dependent kinase 4 (CDK4) amplification. To identify these amplified junctions, whole genome sequencing was performed on resected tissue. Primers were designed to flank junction breakpoints and were then utilized on each patient’s plasma samples to detect the amplified junction via qPCR. Tumor-specific amplified junctions were robustly detected in plasma from 14/14 (100%) patients with IDH-mutant or wild-type grade 4 astrocytomas whose tumor genomes demonstrated amplification-related junctions, located at chromosomes 7, 11, or 12. In comparison, ctDNA could not be detected in three control cases that did not have an amplification or did not have high copy number junctions. Importantly, serial plasma samples obtained prior to and at disease recurrence in 4 patients demonstrated an increasing abundance of amplified junctions that accurately correlated with disease progression in 4/4 patients (100%). In two of these patients, increasing abundance of amplified junctions preceded radiographic changes compatible with disease progression by approximately 2 or 4 months, respectively. In conclusion, tumor-specific amplified junctions could reliably be detected in plasma from patients with IDH-mutant or wild-type grade 4 astrocytomas and correlated with changes in disease burden. Further work is currently ongoing to evaluate these promising results in a larger cohort of patients with serial plasma samples.
Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone
Norton, Emily S. , Whaley, Lauren , Jones, Vanessa K. , Brooks, Mieu, Russo, Marissa , Morderer, Dmytro , Jessen, Erik , Carrano, Anna , Asmann, Yan W. , Lam, TuKiet T. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Guerrero‐Cazares, Hugo , Whaley, Lauren A , Brooks, Mieu M, Russo, Marissa N., Schiapparelli, Paula , Zarco, Natanael , Carrano, Anna , Rossoll, Wilfried , Asmann, Yan W , Lam, TuKiet T , Anastasiadis, P Z , Guerrero-Cazares, Hugo , Ramos‐Fresnedo, Andres , Zarco, Natanael

Mayo Clinic

Science Advances | August 7, 2024 | Volume: 10 | Issue: 32 | Pages: No page available

10.1126/sciadv.adn1607 | PMID 39110807 Get It

Glioblastoma (GBM) is the most prevalent and aggressive malignant primary brain tumor. GBM proximal to the lateral ventricles (LVs) is more aggressive, potentially because of subventricular zone contact. Despite this, cross-talk between GBM and neural stem/progenitor cells (NSC/NPCs) is not well understood. Using cell-specific proteomics, we show that LV-proximal GBM prevents neuronal maturation of NSCs through induction of senescence. In addition, GBM brain tumor–initiating cells (BTICs) increase expression of cathepsin B (CTSB) upon interaction with NPCs. Lentiviral knockdown and recombinant protein experiments reveal that both cell-intrinsic and soluble CTSB promote malignancy-associated phenotypes in BTICs. Soluble CTSB stalls neuronal maturation in NPCs while promoting senescence, providing a link between LV-tumor proximity and neurogenesis disruption. Last, we show LV-proximal CTSB up-regulation in patients, showing the relevance of this cross-talk in human GBM biology. These results demonstrate the value of proteomic analysis in tumor microenvironment research and provide direction for new therapeutic strategies in GBM.